Preventive Cardiovascular

Impact of Preventive Cardiology on HgbA1c Levels Among Patients With Diabetes

Impact of Preventive Cardiology on HgbA1c Levels in Diabetic Patients

2023, N =245

Preventive cardiology patients who are diabetic and had an HgbA1c level of 7% or higher at baseline experienced reductions in their HgbA1c levels. Baseline is defined as the patient's first visit. Follow-up data are from the most recent visit. Patients included in these data had at least 2 follow-up visits in the past 2 years.

​

​

Source: EPIC

Diabetic Patients with a Baseline HgbA1c ≥7 on GLP-1 at Most Recent Follow –up

2023, N = 98

There is an increased utilization of GLP-1 agonists in the Preventive Cardiology clinic for the treatment of diabetes. Preventive Cardiology patients who are diabetic and had a HgbA1c of 7% or higher are included in this data.

Baseline is defined as the patient’s first visit. Follow up data are from the most recent visit. Patients included in this data has at least 2 follow ups in the last 2 years.

Source: EPIC

Diabetic Patients with a Baseline HgbA1c ≥7 on SGLT-2 at Most Recent Follow –up

2023, N = 113

There is an increased utilization of SGLT-2 Inhibitors in the Preventive Cardiology clinic for the treatment of diabetes. Preventive Cardiology patients who are diabetic and had a HgbA1c of >7% are included in this data.

Baseline is defined as the patient’s first visit. Follow up data are from the most recent visit. Patients included in this data has at least 2 follow ups in the last 2 years.

Source: EPIC